This study is looking at how well Dupixent (dupilumab 300mg) works when combined with narrowband UVB phototherapy for people with moderate to severe atopic dermatitis (a type of eczema). You may be able to join if you are an adult aged 18 or older with moderate to severe atopic dermatitis, meaning you have an EASI score of 16 or higher, an IGA score of 3 or higher, and at least 10% of your body affected. You cannot have used Dupixent before or be allergic to it. The researchers will know the treatment is successful if your skin clears up significantly, measured by an Investigators Global Assessment Score of 0 or 1, after 12 weeks. The current recruitment status is unclear.

Study design

This is an open-label study, meaning both you and the study team will know what treatment you are receiving. It plans to enroll 40 participants.

What's involved

You would receive Dupixent and narrowband UVB phototherapy three times a week for 12 weeks, followed by 12 weeks of Dupixent alone.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at 12 weeks, but the study lasts for 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.